Pharmaceuticals · Key players

Top KRAS Inhibitors companies

The 5 key players our KRAS Inhibitors report profiles, and other companies free public records show in this market.

Key players in KRAS Inhibitors

In the order our report profiles them, not ranked by sales. Each name opens the company's page with its public records.

Key players in the KRAS Inhibitors market
#CompanyWebsiteOur reports
1 Amgen Inc. amgen.com (opens in a new tab) 693 reports
2 Bristol-Myers Squibb bms.com (opens in a new tab) 627 reports
3 Eli Lilly and Company lilly.com (opens in a new tab) 1,056 reports
4 Revolution Medicines — 33 reports
5 Novartis AG novartis.com (opens in a new tab) 1,551 reports

Also active in KRAS Inhibitors

Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.

Also active in KRAS Inhibitors, from free public records
CompanyWhere public records show them
Verastem, Inc.
Bristol Laboratories Ltd
Merck & Co., Inc.
Mirati Therapeutics Inc.
Roche
Genfleet Therapeutics (Shanghai) Inc.
Allist Pharmaceuticals, Inc.
AstraZeneca
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Jiangsu HengRui Medicine Co., Ltd.
Boehringer Ingelheim GmbH
Kumquat Biosciences Inc.

Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.

Top trial sponsors in KRAS Inhibitors

Companies leading the most active studies found with this market's trial search, worldwide (key players included).

  1. Revolution Medicines 15 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Merck & Co., Inc. 10 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Verastem, Inc. 10 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Mirati Therapeutics Inc. 8 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Roche 8 active trials on ClinicalTrials.gov (opens in a new tab)
  6. Genfleet Therapeutics (Shanghai) Inc. 7 active trials on ClinicalTrials.gov (opens in a new tab)
  7. Eli Lilly and Company 7 active trials on ClinicalTrials.gov (opens in a new tab)
  8. Allist Pharmaceuticals, Inc. 6 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

KRAS Inhibitors reports by place

All 33 places for KRAS Inhibitors

Get the full KRAS Inhibitors report

Company profiles, market shares and strategies come with the full report, with researched size, forecast, growth and segments.

Buy the full report Request free sample

Key players are our report's research. Other companies and trial counts come from free public records, each with its source. Acuitas market figures are not published on this page.